摘要:
This invention relates to oxetanocin-related compounds represented by the following formula (I): ##STR1## [in formula (I), R.sub.1, Y and B have the following meanings: (a) R.sub.1 represents --CH.sub.2 OH or --CH.sub.2 OCO-(alkyl),(b) Y represents ##STR2## provided that R.sub.2 is --H, --OH or --CH.sub.2 OH and R.sub.3 is --H, --OH, halogen atom, --CH.sub.2 OH, lower alkyl group, --CH.sub.2 -N.sub.3, --CH.sub.2 -F, --N.sub.3, --COOH, --NH.sub.2, --CH.sub.2 OSO.sub.3 H or --CH.sub.2 OCO-(lower alkyl), and(c) B represents a residue of purine base,(d) provided that R.sub.1 and R.sub.3 cannot simultaneously represents --CH.sub.2 OH]and their salts which have activities such as an antiviral activity and the like and are expectedly useful as a pharmaceutical and the like.
摘要:
The present invention relates to phosphoric acid esters of oxetanocins having an antiviral activity which are represented by general formula (I): ##STR1## wherein R.sub.1 represents a phosphoric acid ester residue, X represents hydrogen, hydroxy or hydroxymethyl group, and B represents a purine base residue, and pharmacologically acceptable salts thereof.
摘要:
This invention relates to novel oxetanocins represented by the following general formula (I): ##STR1## wherein R represents a group represented by ##STR2## and their pharmacologically acceptable salts which have antiviral activities.
摘要:
It was found that 2-halogeno-oxetanocin A and 4'-phosphate thereof represented by the following general formula (1): ##STR1## wherein X represents a halogen atom and R represents a hydrogen atom or a phosphoric acid residue ##STR2## or salts thereof exhibit a strong antiviral activity and are useful as an active ingredient of therapeutic drug for viral diseases. Further, it was also found that the compounds of this invention are characterized in that they are not inactivated by adenosine deaminase widely present in living bodies and exhibit a high residual activity.
摘要:
A novel nucleic acid derivative represented by the following general formula (I) and physiologically acceptable salt thereof which are expected to have an antiviral activity: ##STR1## wherein B represents a nucleic acid base derivative; A.sup.1 and A.sup.2 represent, independently of each other, OR.sup.1 or OCOR.sup.1 ; R.sup.1 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; l represents a number of 0 or 1; and m and n each represents an integer of 0-2; provided that when l and m are 0, n is 0 or 2.
摘要:
The present invention relates to a novel compound having hypoxanthine base represented by the following formula: ##STR1## as well as to use of said compound and process for producing said compound.The novel compound of the present invention has an immunosuppressive and antiviral actions and is expected to be useful as a medical drug.
摘要:
A pharmaceutical composition for inhibiting Human Immunodeficiency Virus (HIV), which is characterized by comprising a compound represented by the formula (1) ##STR1## or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要:
Oxetanocin derivatives represented by formula: ##STR1## wherein X represents H or ##STR2## or a pharmacologically acceptable salt thereof exhibit an anti-viral activity. Anti-viral compositions comprising the oxetanocin derivatives or their pharmacologically acceptable salts as the effective ingredient are also provided.
摘要:
The present invention provides: an anti-HIV composition comprising at least one member selected from the group consisting of trifluridine and derivatives thereof, and a pharmaceutically acceptable carrier; an anti-HIV composition comprising (a) at least one member selected from the group consisting of trifluridine and derivatives thereof, (b) a thymidine phosphorylase inhibitor, and a pharmaceutically acceptable carrier; and a composition for potentiating the anti-HIV activity of trifluridine and derivatives thereof, comprising a thymidine phosphorylase inhibitor and a pharmaceutically acceptable carrier.
摘要:
Now are provided (R)-3,6-diamino-N-(.omega.-aminoalkyl)-hexanamides which are novel compounds having the general formula (I): ##STR1## wherein n stands for 2-5, and which may be for example, (R)-3,6-diamino-N-(2-aminoethyl)hexanamide (n=2) and (R)-3,6-diamino-N-(3-aminopropyl)hexanamide (n=3). Their preparation process is also provided. These novel compounds and acid addition salts thereof have activities inhibitory against Gram-positive bacteria, Gram-negative bacteria and AIDS virus, as well as tumor cells and are chemically stable. These novel compounds and their salts are useful as chemotherapeutic agents for diseases caused by these bacteria or virus and also as antitumor agent.